Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: GlobeNewswire
Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team Zevra Continues Growth Trajectory into a Global Commercial Rare Disease Company with Consistent Execution, New Product Launches, and Significant Financial Flexibility to Execute Strategic Plan Urges Stockholders to Defend Board Independence from Majority Influence by Individual 2.8% Stockholder, Mangless, Who Had Three Nominees Elected to the Board in 2023 Mangless Has Not Detailed any Strategies, Plans, or New Ideas to Improve Zevra’s Business and Appears Solely Focused on Replacing Two Highly Qualified Directors Board and Management Urge Stockholders to Vote "FOR" Zevra’s Highly-Qualified and Experienced Director Nominees on the WHITE Proxy Card CELEBRATION, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra”, or “the Company”), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it has filed i
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? [Yahoo! Finance]Yahoo! Finance
- Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhDGlobeNewswire
- Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 12/17/25 - Form 8-K
- 12/9/25 - Form 4
- 12/9/25 - Form 3
- ZVRA's page on the SEC website